A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- Registration Number
- NCT00002369
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
To evaluate the tolerance, and comparative virologic and immunologic effects of the two combination regimens.
- Detailed Description
100 patients will be randomized to receive Zerit (Stavudine) + Epivir (Lamivudine) + Crixivan (Indinavir) and 100 patients will be randomized to receive Retrovir (Zidovudine) + Epivir (Lamivudine) + Crixivan (Indinavir).
Patients will be treated for 48 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (11)
San Juan AIDS Program
🇵🇷Santurce, Puerto Rico
Boston Univ Med Ctr Hosp / Evans - 556
🇺🇸Boston, Massachusetts, United States
HIV Clinical Research Ctr
🇺🇸Fort Lauderdale, Florida, United States
Blackstock Family Health Ctr
🇺🇸Austin, Texas, United States
Univ of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Louisiana State Univ Med Ctr / HIV Outpatient Clinic
🇺🇸New Orleans, Louisiana, United States
Community Research Initiative of New England
🇺🇸Brookline, Massachusetts, United States
Infectious Disease Research Institute Inc
🇺🇸Tampa, Florida, United States
Washington Univ School of Medicine
🇺🇸St Louis, Missouri, United States
Advance Clinical Research
🇺🇸Atlanta, Georgia, United States
Hosp Regional de Ponce - Area Vieja
🇵🇷Ponce, Puerto Rico